
CUA Annual Meeting and
Lunch Tuesday, October 30, 2007 (12:00pm - 1:30pm) During
the Western Section AUA 83rd Annual Meeting MORE INFO...
Western Section AUA - 83rd
Annual Meeting October 28 - November 1, 2007 Hyatt
Regency Resort & Spa, Scottsdale, AZ MORE INFO...

|

QUESTION & ANSWER Jeffrey Kaufman, M.D.
Should I send additional information, from another
date of service, which was not requested, that supported the use for
Mitocycin C rather than BCG, the lower cost drug? Are non
participating physicians receiving repayment requests? Are
retired physicians receiving repayment requests? READ
MORE...

California Urological
Association 1950 Old Tustin Ave. Santa Ana, CA 92705 TEL:
714-550-9155 FAX: 714-550-9234 EM:info@cuanet.org WEB: www.cuanet.org
|

Effective September 17 - the NPI/Legacy ID Combinations Must
Match By
NHIC, CORP.
Members:
CMS
recently announced that contractors should begin editing and rejecting
claims that do not match on the NPI crosswalk file. This essentially means that any solo incorporated
physician (who also needed both a type I and type II NPI number) should
have re-enrolled in the Medicare program using the 8551 form. If
they haven't they wouldn't know that a problem loomed since they are
currently still being paid on the basis of their legacy (old fashioned)
identifier. However, what this warning means is that if they don't
submit the 8551, when NHIC ceases to accept the old identifier, they won't
be in the system and won't be paid. If they delay submitting until
they see the problem, they may still be paid but it will delay payments
quite a long time causing considerable hardship.
See full text of letter from NHIC below.
Dr.
Jeffrey Kaufman.
Since October 2, 2006,
providers have been encouraged to submit both the NPI and Medicare legacy
identifier (PIN) on their claims.
During this timeframe providers were not
penalized for invalid NPI/legacy ID combinations.
Effective September
17, 2007, NHIC, Inc. will begin editing the NPI/legacy ID combinations for
validity against the NPI crosswalk file. Where a match cannot be located
on the crosswalk, claims will be rejected or returned to the
provider.
When the claim is
returned, a provider should first verify that the correct NPI was
submitted. If correct, you
will need to verify that your legacy identifier (PIN) number corresponds
with the information on file with the National Plan and Provider
Enumeration System (NPPES). NPPES data may be checked on line at https://nppes.cms.hhs.gov.
If your NPPES
information is correct and you have included and matched ALL Medicare
legacy identifiers with a corresponding NPI in NPPES, but you are
experiencing provider identifier problems with your claims that contain an
NPI, you may need to submit a Medicare enrollment application (i.e., the
CMS-855). Please contact
Customer Service at 877-527-6613 if
you need more information.
More information
and education on the NPI may be found at the CMS NPI page, http://www.cms.hhs.gov/NationalProvIdentStand
on the CMS website. Also, providers can apply for an NPI online at
https://nppes.cms.hhs.gov.
If your claims are
processing properly with the NPI / Legacy cross-walk, we urge you to send
a small batch of 3-10 claims with the NPI number only to
validate that the cross-walk of the legacy number, formerly Provider
Identification (PIN) or Provider Transaction Access Number (PTAN), with
the NPI is correct. This
approach will be helpful in detecting any NPI problems for the provider
without effecting cash flow.
Thank you for your assistance in getting
the word out about this change.
NHIC, Corp. 1055 West 7th Street, Suite 500 Los
Angeles, CA 90017
UROLOGY ANCILLARY REVENUE CMS Proposed Regulations - An Update and Additional
Guidance
Click for Guideline Letter
As reported
last month, on July 2nd the Center for Medicare and Medicaid
Services (CMS) issued the Medicare Physician Fee Schedule (MPFS) Proposed
Rules that, if finalized, could materially negatively affect many urology
ancillary revenue opportunities.
In this letter we will provide additional clarification of the MPFS
proposed rules, as well as guidance to assist you in submitting comments
to CMS before the August 31, 2007 deadline. Through your comments to CMS, you
can make a difference in preserving the quality of patient care provided
by the urological community, while also protecting urologists' ability to
participate in ancillary revenue opportunities.
A. Proposed
Regulation Stark Law Changes
The new MPFS
proposed rules, if finalized, would make sweeping changes to the Federal
Stark law. The Stark Statute
prohibits a physician from making referrals to an entity, with which the
physician or his immediate family has a financial interest, for the
furnishing of specified designated health services (DHS) under Medicare,
unless an exception applies.
Targeted financial interests include compensation arrangements and
ownership arrangements. The
new MPFS proposed rule suggests changes to the Stark Statute and its
regulatory exceptions that could limit many urology ancillary revenue
opportunities.
1.
Services
Furnished Under Arrangements. The Medicare statute permits
providers, such as hospitals, to furnish services to beneficiaries "under
arrangements" with third party vendors. Lithotripsy and bph laser services
are commonly provided by urologist-owned vendors that contract under
arrangements with hospitals.
Historically, CMS interpreted "entity" under the Stark Statute to
only mean the entity billing for the service in an under arrangement
contract, which would be the hospital. The Stark financial interest in
such circumstance would be a compensation arrangement between the hospital
and physician owned vendor, and most urologist-owned lithotripsy and bph
vendors have historically relied on the Stark indirect compensation
arrangement to comply with the Stark law. The new MPFS rule proposes to
change the Stark definition of entity to mean not only the hospital that
bills for the services, but also the person or entity that either provides
the DHS (e.g., the urologist vendor) or "causes a claim to be presented"
for the DHS.
If the
contracting urologist lithotripsy or bph vendor is interpreted to be the
entity "performing" the DHS service or "causing" the claim for DHS to be
presented, then the urologists' ownership interest in the contracting
vendor could require a Stark ownership exception. As there is no applicable Stark
ownership exception under such circumstances, the proposed rule could be
interpreted to prohibit the physician-owned entity from contracting under
arrangements with hospitals for DHS services. However, this is not a foregone
conclusion. What does "causes
a claim to be presented" mean under the new proposed rule? Urologist vendors have little
influence on causing Medicare claims to be presented by a contracting
hospital. Further
clarification is required.
Also, lithotripsy and bph laser services are DHS only if billed by
a hospital. Consequently, if
the Stark "entity" is the urologist-owned vendor, it could be argued that
the urologist vendor is performing non-DHS lithotripsy and bph services,
and not DHS hospital inpatient or outpatient hospital services. Again, further clarification is
required. In the American Lithotripsy Society vs.
Thompson case, the court held that lithotripsy is not a DHS. Consequently, a further argument
exists that a urologist-owned lithotripsy vendor cannot be deemed to be
performing a DHS service that requires a Stark ownership exception. There is also legislative history
that supports that Congress intended that under arrangements contracts
only require a Stark compensation exception, and not an ownership
exception, which raises questions whether CMS has the authority to issue
regulations contrary to congressional
intent.
2.
Unit of
Service (Per-Click) Payments. Most service arrangements between
urologist vendors and hospitals provide for payment for services on a per
procedure basis. Current
Stark regulations for space and equipment leases (and personal services)
allow payment on a per procedure basis. Under the new proposed
regulations, the Stark equipment lease and space rental exceptions would
be modified to prohibit per unit of service rental charges. Consequently, an individual
urologist would no longer be allowed to lease a bph laser or lithotripter
to a hospital for a per procedure fee. It should be noted, however, that
the new proposed rule does not contemplate adding a similar prohibition to
the personal services exception or indirect compensation arrangements
exception. The latter
exception is relied upon by most urologist vendors in their leases of
equipment to hospitals. There
is danger, however, that the new regulations could be modified to apply to
indirect compensation arrangements.
CMS has also hinted that it may modify the indirect compensation
arrangement definition in the anticipated Stark III regulations. It is likely that the future Stark
III regulations will collapse together individual physicians with their
group practices in any revised indirect compensation arrangement
definition, which would trigger the use of the direct equipment rental
Stark exception, and the corresponding per procedure rent prohibition
under the proposed MPFS regulation.
It is uncertain whether the impending Stark III regulations would
also collapse together joint ventures with their physician owners. Any attempt by CMS to prohibit per
procedure payments, however,
will be subject to serious challenge on the basis that it is
contrary to clear congressional intent, as expressed in the Stark
legislative history, to permit per procedure payments under the Stark
exceptions.
3.
Restriction on
Percentage Fee Payments. Several important Stark exceptions
require that compensation be "set in advance;" e.g., personal service
arrangements, fair market value compensation, and the office and equipment
lease exceptions.
Historically, CMS interpreted the "set is advance" requirement to
permit percentage fee payments.
In the proposed MPFS rule, CMS would change the "set in advance"
definition to prohibit percentage based fees, except for professional
services. The proposed
regulations would prohibit an individual urologist from directly leasing
equipment to a hospital in exchange for a percentage fee. It is notable, however, that the
Stark indirect compensation arrangement exception does not have a "set in
advance" requirement, so the proposed percentage fee prohibition would not
appear to apply to urology practices or typical urologist joint venture
equipment lease arrangements with hospitals. As discussed previously, there is
a danger that the new proposed regulations may be modified to extend the
percentage fee prohibition to physician practice and joint venture
equipment lease arrangements.
The anticipated Stark III regulations could also negatively modify
the indirect compensation arrangement
exception.
4.
In-Office
Ancillary Services Exception. The Stark Statute in-office
ancillary services exception allows a physician to furnish and benefit
from many ancillary services that are DHS, as long as the services are
provided in the physician's office and certain other requirements are
met. Specifically, urologists
rely on this exception to provide path lab, CT imaging and IGRT/IMRT
within their individual group practices. In its commentary to the proposed
MPFS rules, CMS expresses concern that the in-office ancillary services
exception is being used to allow physicians to benefit financially from
referrals that are not closely related to a physician's professional
practice. CMS expresses
particular concern with growing reliance on the exception to allow
in-office path labs and use of expensive imaging equipment in physicians'
offices. Without proposing
new regulations, CMS solicits comments on whether changes are needed to
the in-office ancillary services exception to stop perceived program
abuse. CMS specifically
requests comments on (i) whether certain services not fully integrated
into a practice should be excluded from the exception, (ii) whether
changes should be made to the exception to limit where the ancillary
services can be performed, and (iii) whether non‑specialists (e.g.,
urologists) should be allowed to use the exception for specialty services
(e.g., anatomical pathology, external beam radiation and CT imaging)
involving equipment owned by the non‑specialist (e.g., path lab equipment,
IGRT/IMRT and CT). CMS has
hinted that the anticipated Stark III regulations may modify the in-office
ancillary services exception to at least shut down off-site anatomical
path labs. In drafting the
Stark law, Congress specifically excluded certain DHS from the exception
(e.g., durable medical equipment), which raises questions whether CMS has
the independent authority to exclude any other DHS services not
contemplated for exclusion by Congress.
5.
"Stand in
the Shoes". In the MPFS commentary, CMS
solicits comments, without issuing a rule, on providing additional
restrictions on "indirect" relationships involving multiple DHS
entities. Specifically, CMS
proposes that where a DHS entity (e.g., a hospital) owns or controls
another entity (e.g., an ambulatory surgery center) to which a physician
refers Medicare patients for DHS, the controlling and controlled DHS
entities would be collapsed together so that the referring physician would
be deemed to have a compensation arrangement with the controlling
entity. This is a complicated
provision and it has many applications, but in the context of urology
ventures, it will most likely have the greatest impact on urologist-owned
bph laser and lithotripsy vendors contracting with ambulatory surgery
centers (ASC) owned or controlled by hospitals. Bph laser and lithotripsy services
only trigger the Stark Statute when they are provided at hospitals, so
traditionally those services don't have to comply with a Stark exception
when provided at an ASC.
Under the CMS proposal, however, a hospital-owned or controlled ASC
would be collapsed into the hospital, and a urologist-owned bph laser or
lithotripsy vendor contracting with the ASC would have to comply with
Stark. Note that under other
regulations published by CMS, it is anticipated that Medicare will
reimburse lithotripsy services performed at ASCs beginning in
2008.
B. Proposed
Reassignment/Purchased Diagnostic Test Rules
Under the
existing Medicare purchased diagnostic test rule, if a physician bills the
technical component of a diagnostic test performed by an outside supplier,
the physician is required to bill Medicare the lower of the Medicare
reimbursement for the technical service, or the amount charged to the
practice by the outside supplier for the technical service. This old rule essentially
prohibits a physician from profiting from the purchase of the technical
component of a diagnostic test performed by an outside supplier. The new MPFS proposed rules
expands this concept to the professional component of diagnostic tests as
well. Consequently, under the
new proposed rule if a urology practice owns and operates imaging or lab
equipment in its office, and globally bills Medicare for both the
technical and professional components of the related service, the practice
cannot make any profit on the professional component of the service,
unless the professional performing the services is a full-time employee of
the urology practice.
Therefore, if the party providing the professional component (e.g.,
pathologist or radiologist) is a part-time employee or independent
contractor, or full–time independent contractor, then either the entire
Medicare professional component must be paid to such party by the urology
practice, or the global fee professional component billed to Medicare must
be reduced to reflect the amount actually paid to such professional. The proposed rules also prohibit a
urology practice from offsetting against the professional fee paid to the
outside physician (e.g., pathologist or radiologist) any billing and
collection administrative expenses, or other overhead costs.
It should be
stressed that the July 2nd MPFS rules are proposed only and do
not change the current laws under which urologists provide ancillary
services.
C.
Guidance on
Submitting Your Comment Letter to CMS
The deadline
for submitting your written comments to CMS regarding the proposed MPFS
rule is 5:00 p.m. August 31.
It is very important that CMS hears from you, and from as many
other individual urologists as possible, regarding the unfairness of the
proposed rules, and the negative impact they would have on patient access
to the most innovative medical
technologies.
1.
Guidance in
Submitting Written Comments. In Sections A and B of this
Update, we highlight the most material provisions of the proposed rules
that could negatively impact ancillary urology revenue opportunities, and
those provisions should be the focus of your comments. CMS gives little to no weight to
mass prepared form letters, so it is important that you prepare your own
individual comments that reflect your personal circumstances and
concerns. Given the
complexity of the proposed regulations, we appreciate that preparing an
individual comment letter can be a daunting task. If you would like additional
assistance in preparing your comment letter, please contact us at [add
organization e-mail address here], and we will e-mail you a guideline with
bullet points relating to each material proposed regulation provision for
you to consider incorporating into your own letter. Although there are strong legal
arguments that certain proposed provisions shouldn't apply to many
ancillary urology revenue opportunities, comments must direct CMS to
clarify the proposed regulations to ensure contracting hospitals will
accept such arguments.
2.
U.S. Mail Written
Comments. Written responses must be received
by CMS by 5:00 p.m. August 31, 2007.
If you plan to submit your comments by regular U.S.
mail, then you should post them (one original and two copies) no later
than August 27, 2007 to the address
below:
Center for Medicare and Medicaid Services
Department of Health and Human Services
Attention:
CMS-1385-P
P.O.
Box 8018
Baltimore, MD 21244-8018
3.
Overnight Mail
Written Comments. If you are going to overnight mail
your written comments, they should be posted (one original and two copies)
no later than August 30, 2007 to the address
below:
Center for Medicare and Medicaid Services
Department of Health and Human Services
Attention:
CMS-1385-P
Mail Stop C4-26-05
7500 Security
Boulevard
Baltimore, MD 21244-1850
4.
Electronic
Mailed Comments. You may submit electronic mail
comments before 5:00 p.m. August 31, 2007 by clicking on the following web
link http://www.cms.hhs.gov/eRulemaking. Once on the website, click on the
link "Submit electronic comments on CMS regulations with an open comment
period" and follow the instructions.
Emailed
attached comments may be in WordPerfect, Microsoft Word or Excel
formats.
We encourage
you to timely submit your comments to CMS in order to protect your
patients access to high quality urology services, and preserve your
opportunity to participate in urology ancillary revenue opportunities.
This
Update on the new proposed regulations was prepared and submitted by Greg
L. Smith, a healthcare attorney practicing with Womble Carlyle Sandridge
& Rice, PLLC, and specializing in urology-based ancillary revenue
opportunities. Greg can be
reached at gsmith@wcsr.com and
336-721-3665.
Question
& Answer:
Lupron
Jeffrey Kaufman, M.D.,
F.A.C.S.
QUESTION
Dear
Dr. Kaufman:
Thank you for your tremendous efforts in dealing with
the Lupron repayment crises.
PRG Schultz has now embarked in other
endeavors and have requested records with
Mitomycin C instillations.
They have not requested the
documentation supporting the use of Mitomycin C instillation, only the
code for Mitoymycin C. Of course, they made it difficult to identify
the patient, by not including their name, but only stating their Medicare
number and the date of service.
Should I send additional
information, from another date of service, which was not requested, that
supported the use for Mitocycin C rather than BCG, the lower cost
drug? There was no charge for an EM service on the date of
instillation, only the charge for instillation and Mitomycin C. The
documentation is for 40 mg versus 20 mg.
I thank you again
for your great efforts in dealing with Lupron. It appears that PRG
Shultz may go after all drug treatments for the lowest cost payment, which
should create a greater uproar for medical specialties that administer
parenteral medications.
After reading through all the
communications, PRG Schultz expects to collect their monies from direct
re-payments from doctors or from withholds from future Medicare
Payments. Are non participating physicians receiving repayment
requests? Are retired physicians receiving repayment requests?
If they are, will PRG Schultz use a collection agency to collect money due
from those physician categories?
ANSWER
Several
issues are pertinent here. First, be sure the claim date in question
falls within the 4 year scope allowed to them (determined by the date the
claim was paid). Second, I have already complained to CMS and PPAC
that the letters are vague and do not include enough information to allow
you to know what to submit, especially if they don't make it clear what
particular aspect of your care is being investigated. This holds
(obviously) when they don't include the patient name but only refer to the
claim by their internal code. We have already gone round with them
on this and they are SUPPOSED to refer to the patient by name and the
claim by date. Next, in most cases where records are requested, they
are doing a "complex" review to confirm that the care was delivered, was
reasonable and necessary, was billed and paid for correctly and that all
policies were adhered to. I would submit all related documents that
support the indication (such as pathology reports, consults, previous
records showing that this particular treatment is necessary (such as
previous failure to respond to BCG or something about their situation that
specifically warrants mitomicin, etc) even if it is not specifically
requested or pertains to another date of service. Remember, these
charts are reviewed by nursing, not doctors and they may have no idea
about proper treatments beyond what they read in some printed
policy. If appropriate and necessary, include a separate
letter translating any abbreviations you use, explaining the
background on this case (such as why you chose mitomicin) and why this
disease warranted treatment in the first place. Finally, if there is
a specific policy on an issue for which records are requested, try to
respond directly to what you suspect they are questioning to head off
trouble prophylactically. HOWEVER, realize that the general policy
that raised questions about LHRH agonists specifically relates to Least
Costly Alternative (not least costly drug). There is no
policy that suggests mitomycin and BCG are alternatives. They are
different drugs used in different situations. While the LCA policy
is based on the concept that Medicare is only charged with paying for
reasonable and necessary treatment (and they don't consider more expensive
alternatives either), they crux of any argument over LCA is whether the
agents compared are truly alternatives. You can't argue that radical
cystectomy and intravesical instillations are reasonable alternatives even
though both treat bladder cancer. Similarly, BCG and mitomycin are used
differently, have different side effects and therapeutic outcomes.
If you had any reason at all for your choice of mitomycin (and I assume
you had some basis for choosing it regardless whether some nurse agrees
with your clinical judgement), you have the right and responsibility to
treat as your training and experience indicate. They cannot deny you
payment for mitomycin based on the LCA policy. If they try, let me
know and I will help you draft an appeal and take the decision to the
highest levels since it exceeds their authoritity to apply policies. I would have to research the BCG
policy but I am fairly certain no one could interpret these two drugs as
alternatives in the was we have considered the term previously. The RAC would be breaking entirely
new ground here and would be challenged.
If
I am correct that they simply can't review this case under the least
costly alternative policy umbrella, then they must be searching to confirm
that the drug was administered consistent with policy (proper indication,
doctor in attendance, dose in chart confirms what was billed, medical
literature supports use, chart fully documents what was done,etc.). Review your records carefully
before sending them and include a letter of explanation or support or
justification if necessary and include all data you think a nurse would
need to understand what you did, why you did it and to believe you did it
correctly and deserve to be paid.
Next issue was that the RAC
doesn't collect money if the appeal is won. And, the carrier NHIC doesn't
withhold money during the time an appeal is considered althought, if you
lose the appeal, you will owe interest from the time the money was first
due. However, this is all dependent on the fact that they feel money was
paid incorrectly and demand recoupment, a decision I would hope doesn't
occur. I hope that answers your questins. Please follow up and let me know
how this turns out. Contact me for any other
questions.
Jeffrey Kaufman,
M.D. CUA
| Questions or Comments? Please CLICK HERE |
Join CUA - CLICK HERE |
Interested Colleagues? Please
Forward |
 |